CY1123481T1 - Cys80 συζευγμενες ανοσοσφαιρινες - Google Patents

Cys80 συζευγμενες ανοσοσφαιρινες

Info

Publication number
CY1123481T1
CY1123481T1 CY20201100992T CY201100992T CY1123481T1 CY 1123481 T1 CY1123481 T1 CY 1123481T1 CY 20201100992 T CY20201100992 T CY 20201100992T CY 201100992 T CY201100992 T CY 201100992T CY 1123481 T1 CY1123481 T1 CY 1123481T1
Authority
CY
Cyprus
Prior art keywords
chain variable
immunoglobulins
conjugated
thiol
immunoglobulin
Prior art date
Application number
CY20201100992T
Other languages
English (en)
Inventor
Luigi Grasso
Jared Spidel
James Bradford KLINE
Earl Albone
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CY1123481T1 publication Critical patent/CY1123481T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Παρεχόμενες στο παρόν είναι μέθοδοι για δημιουργία συζευγμένων ανοσοσφαιρινών, η δε μέθοδος περιλαμβάνει: αποσύνδεση κυστεΐνης στη θέση αμινοξέος 80 («Cys80») σε μεταβλητή περιοχή ελαφράς αλύσου μιας ανοσοσφαιρίνης, όπου η ανοσοσφαιρίνη περιλαμβάνει μεταβλητή περιοχή βαριάς αλύσου και τη μεταβλητή περιοχή ελαφράς αλύσου• και σύζευξη αντιδρώσας με θειόλη ένωσης προς τη Cys80, όπου η αντιδρώσα με θειόλη ένωση περιλαμβάνει αντιδρώσα με θειόλη ομάδα. Μόρια σύνδεσης αντιγόνου και μέθοδοι για δημιουργία αυτών, ανοσοσφαιρίνες καθώς επίσης μόρια νουκλεϊνικού οξέος που κωδικοποιούν τις ανοσοσφαιρίνες και κύτταρα ξενιστές που περιλαμβάνουν τα μόρια νουκλεϊνικού οξέος, συζευγμένες ανοσοσφαιρίνες, και μεταβλητές περιοχές ελαφράς αλύσου για χρήση σε συζευγμένη ανοσοσφαιρίνη επίσης παρέχονται.
CY20201100992T 2015-06-19 2020-10-20 Cys80 συζευγμενες ανοσοσφαιρινες CY1123481T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562182020P 2015-06-19 2015-06-19
PCT/US2016/038041 WO2016205618A1 (en) 2015-06-19 2016-06-17 Cys80 conjugated immunoglobulins

Publications (1)

Publication Number Publication Date
CY1123481T1 true CY1123481T1 (el) 2022-03-24

Family

ID=56404289

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100992T CY1123481T1 (el) 2015-06-19 2020-10-20 Cys80 συζευγμενες ανοσοσφαιρινες

Country Status (33)

Country Link
US (3) US10273310B2 (el)
EP (2) EP3795591B1 (el)
JP (2) JP6823606B2 (el)
KR (1) KR20180021807A (el)
CN (1) CN107949575B (el)
AU (1) AU2016280190B9 (el)
BR (1) BR112017027252A2 (el)
CA (1) CA2989637C (el)
CL (1) CL2017003273A1 (el)
CO (1) CO2017013303A2 (el)
CY (1) CY1123481T1 (el)
DK (2) DK3310816T3 (el)
ES (2) ES2829251T3 (el)
HK (1) HK1252625A1 (el)
HR (1) HRP20201489T1 (el)
HU (2) HUE064407T2 (el)
IL (1) IL256263B (el)
LT (1) LT3310816T (el)
MA (1) MA44207B1 (el)
MD (1) MD3310816T2 (el)
MX (1) MX2017016674A (el)
MY (1) MY189024A (el)
PE (1) PE20180498A1 (el)
PH (1) PH12017502352A1 (el)
PL (1) PL3310816T3 (el)
PT (1) PT3310816T (el)
RS (1) RS60943B1 (el)
RU (1) RU2756101C2 (el)
SG (1) SG10201913935RA (el)
SI (1) SI3310816T1 (el)
UA (1) UA124830C2 (el)
WO (1) WO2016205618A1 (el)
ZA (2) ZA201708619B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4055053A1 (en) 2019-11-07 2022-09-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
JP7399305B2 (ja) * 2020-02-12 2023-12-15 イーライ リリー アンド カンパニー 抗体または抗原結合フラグメントの結晶化
CA3184645A1 (en) 2020-06-05 2021-12-09 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
CN112694521B (zh) * 2020-12-02 2023-01-17 杭州百凌生物科技有限公司 一种人工多肽lh、其抗体及在病理检测中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187094C (zh) * 1998-04-28 2005-02-02 应用研究系统Ars股份公司 多元醇干扰素β偶联物
US6904369B1 (en) * 2000-06-29 2005-06-07 The Trustees Of Columbia University In The City Of New York Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor
US7402409B2 (en) 2003-01-23 2008-07-22 Epitomics, Inc. Cell fusion method
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2006017759A2 (en) * 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
JP5791895B2 (ja) * 2007-05-04 2015-10-07 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 遺伝子操作されたウサギ抗体可変ドメイン及びその使用
EP2162469A4 (en) * 2007-05-21 2012-08-01 Alderbio Holdings Llc NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES
US20110033378A1 (en) * 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
EP2842575B1 (en) 2008-03-18 2017-09-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2010118203A2 (en) 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
CN114246952A (zh) * 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
AR082205A1 (es) * 2010-07-12 2012-11-21 Covx Technologies Ireland Ltd Conjugados de anticuerpos multifuncionales
CN102008732B (zh) * 2010-11-08 2012-10-24 武汉华耀生物医药有限公司 一种叶酸偶联抗体药物及其制备方法与应用
CA2882753C (en) 2012-08-21 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
RS58928B1 (sr) * 2012-08-29 2019-08-30 Hoffmann La Roche Transporter za krvno-moždanu barijeru
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions

Also Published As

Publication number Publication date
IL256263B (en) 2022-06-01
PH12017502352A1 (en) 2018-06-25
PE20180498A1 (es) 2018-03-09
MX2017016674A (es) 2018-08-01
AU2016280190B9 (en) 2022-05-19
MA44207B1 (fr) 2020-11-30
JP6823606B2 (ja) 2021-02-03
AU2016280190B2 (en) 2022-04-28
CN107949575A (zh) 2018-04-20
DK3310816T3 (da) 2020-10-12
HUE051315T2 (hu) 2021-03-01
ZA201708619B (en) 2022-11-30
ES2967613T3 (es) 2024-05-03
KR20180021807A (ko) 2018-03-05
RU2017146220A (ru) 2019-07-19
LT3310816T (lt) 2020-11-25
US20190202933A1 (en) 2019-07-04
HK1252625A1 (zh) 2019-05-31
IL256263A (en) 2018-02-28
HRP20201489T1 (hr) 2020-12-11
NZ738496A (en) 2023-08-25
RU2756101C2 (ru) 2021-09-28
CO2017013303A2 (es) 2018-03-20
US11129904B2 (en) 2021-09-28
MY189024A (en) 2022-01-20
SG10201913935RA (en) 2020-03-30
ZA202102093B (en) 2023-03-29
PT3310816T (pt) 2020-10-19
US20230001004A1 (en) 2023-01-05
EP3310816A1 (en) 2018-04-25
BR112017027252A2 (pt) 2018-08-28
JP7042876B2 (ja) 2022-03-28
EP3310816B1 (en) 2020-09-09
RS60943B1 (sr) 2020-11-30
MD3310816T2 (ro) 2021-01-31
UA124830C2 (uk) 2021-12-01
MA44207A (fr) 2018-12-26
HUE064407T2 (hu) 2024-03-28
US10273310B2 (en) 2019-04-30
SI3310816T1 (sl) 2020-12-31
CA2989637A1 (en) 2016-12-22
CN107949575B (zh) 2022-03-08
US20160369011A1 (en) 2016-12-22
EP3795591B1 (en) 2023-09-27
CA2989637C (en) 2023-01-10
CL2017003273A1 (es) 2018-12-21
ES2829251T3 (es) 2021-05-31
JP2020178717A (ja) 2020-11-05
WO2016205618A1 (en) 2016-12-22
RU2017146220A3 (el) 2019-11-07
PL3310816T3 (pl) 2020-12-14
AU2016280190A1 (en) 2018-01-18
EP3795591A1 (en) 2021-03-24
DK3795591T3 (da) 2024-01-02
JP2018526975A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
CY1123481T1 (el) Cys80 συζευγμενες ανοσοσφαιρινες
CY1119647T1 (el) Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων
CY1117203T1 (el) Διαλυτα «βαριας αλυσιδας-mono» αντισωματα
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CY1123215T1 (el) Πολυνουκλεοτιδια τα οποια κωδικοποιουν αντισωματα τρωκτικων με ανθρωπινους ιδιοτυπους και ζωα τα οποια διαθετουν αυτα
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
CY1120412T1 (el) Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31
EA201591814A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
BR112015023418A2 (pt) conjugado de anticorpo e fármaco, anticorpo ou fragmento de ligação de antígeno, seus processos de produção, seus usos, ácido nucleico, vetor, e célula hospedeira
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
PE20150023A1 (es) Proteinas de union a antigeno st2
WO2012064733A3 (en) Antibody scaffold for homogenous conjugation
ES2620264T3 (es) Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
PE20180481A1 (es) Anticuerpos de union a tau
CL2017000756A1 (es) Moléculas de unión, especialmente anticuerpos, que se unen a l1cam (cd171)
EA201690171A1 (ru) Улучшенный способ получения моноклональных антител
CY1123425T1 (el) Ειδικα για ton rsv αντισωματα και λειτουργικα τμηματα αυτων
CY1123743T1 (el) Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
CY1122728T1 (el) Αντισωματα εναντι hpa-1a